Helsinki-based MVision AI has raised €5.4 million in a post-seed funding round to accelerate cancer treatment automation and expand its reach, says the start-up in a press release. MVision AI, a cloud-based software service provider for radiotherapy treatment planning, uses artificial intelligence to automate cancer treatment.
The AI-powered automatic segmentation tool helps standardise contouring and automate segmentation to streamline the radiotherapy treatment planning workflow, producing consistent contouring in minutes while maintaining the highest standards of quality for every patient, every time.
The groundbreaking technology reduces treatment waiting times from weeks to days and has already been used to treat over 100,000 cancer patients across 14 countries. By developing new solutions and building a globally scalable cloud-based platform, MVision AI aims to make same-day cancer treatment the new global standard, addressing the increasing prevalence of cancer worldwide.
Impressive results
Evaluations of MVision AI’s platform have demonstrated its effectiveness in enhancing patient care by reducing waiting times. The technology has been used in Finland, Sweden, the UK, and other countries. In an evaluation by the Sociedad Española de Oncologia Radioterapica in Madrid, Spain, MVision AI’s technology was found to significantly reduce contouring time and shorten waiting times for patients. After implementing MVision AI, 44 percent of all breast cancer scans were ready to be planned on the same day, compared to only 10% without the AI technology.
Similar wait-time reductions have been achieved in other facilities, including the University of Florida’s Gainesville Department of Radiation Oncology. Chihray Liu, Professor and Chief of Physics at the Gainesville Department of Radiation Oncology, University of Florida, stated, “We were immediately impressed by the quality and consistency of MVision’s AI auto-segmentation… It fits seamlessly and transparently into our workflow”.
